A head-to-head look at oral estradiol and Prometrium (micronized progesterone) covering price, insurance coverage, pharmacy availability, and how the WHI and PEPI trial evidence does and does not apply to this drug pair.
Oral estradiol and Prometrium (micronized progesterone) serve different roles in menopausal HRT. Learn when and how clinicians switch or adjust these components, what the trials show, and how to manage transitions safely.
A clinical guide to switching between transdermal estradiol patches and oral estradiol tablets, covering dose equivalence, safety differences, and step-by-step protocols.
A head-to-head comparison of estradiol transdermal patches and vaginal estradiol covering cost, insurance access, systemic absorption, clinical evidence, and prescribing guidance for menopausal hormone therapy.
A clinical comparison of transdermal estradiol patches and vaginal estradiol, including when and how to switch between them, systemic vs local effects, and what the evidence says about each route.
Oral micronized progesterone and Prometrium are the same molecule. This guide breaks down brand vs generic cost, insurance coverage, pharmacy access, and clinical equivalence for women on HRT.
Oral micronized progesterone and Prometrium contain the identical active ingredient. This clinical comparison breaks down whether brand vs generic formulation differences affect side effects, tolerability, and safety.
Oral micronized progesterone and Prometrium are the same active drug. Learn what differs between generic and brand formulations, how to switch safely, and what clinicians monitor during transitions.
A clinical comparison of Prometrium (micronized progesterone) and vaginal estradiol covering cost, insurance access, indications, and prescribing strategy for women's HRT.
A clinical comparison of Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including when and how to switch between them safely.
Evidence-based exercise protocols for patients with established cardiovascular disease, including post-MI, stroke, PAD, and coronary artery disease. Covers cardiac rehab phases, intensity targets, and safety monitoring.
Compare current ADA, AACE, Endocrine Society, and ACC/AHA recommendations for LDL cholesterol, blood pressure, GLP-1 therapy, and established heart disease.
Depression, anxiety, and PTSD occur at 2-3x the general population rate in patients with established cardiovascular disease. Evidence-based screening and treatment reduce both psychiatric burden and recurrent MACE.
Male hypogonadism shares strong bidirectional links with obesity, type 2 diabetes, metabolic syndrome, cardiovascular disease, osteoporosis, and depression. Learn how these conditions overlap and what guidelines recommend.
For obese men with low testosterone, the Endocrine Society recommends lifestyle change first: 5-10% weight loss, resistance training, 7-9 hours of sleep.
A step-by-step guide to confirming male hypogonadism, identifying its cause, choosing fertility-focused treatment or TRT, and tracking treatment response.
Evidence-based guide for caregivers and family members supporting someone through menopause, including communication strategies, treatment literacy, and when to seek help.
Menopause is confirmed after 12 months without periods, or FSH above 30 mIU/mL on two tests for women under 45. See the full diagnostic steps.
A clinical guide to exercise protocols during menopause, covering resistance training, aerobic activity, and bone-loading strategies, with an honest account of what trial evidence does and does not establish.
Evidence-based, step-by-step menopause treatment algorithm organized by line of therapy. Covers HRT, non-hormonal options, and bone-protective strategies per Endocrine Society, NAMS, and ACOG guidelines.
Evidence-based resources for caregivers and families supporting someone through menopause-related weight gain, including treatment options, diagnostic criteria, and practical support strategies.
An evidence-based guide to the comorbidities linked to menopause-related weight gain, including type 2 diabetes, cardiovascular disease, metabolic syndrome, MASLD, and osteoporosis, with society guideline recommendations.
A step-by-step diagnostic algorithm for menopause-related weight gain, covering hormonal evaluation, metabolic screening, body composition assessment, and evidence-based next steps grounded in Endocrine Society, AACE, and ADA guidelines.
A clinical review of the latest research on menopause-related weight gain, including GLP-1 receptor agonist trials, hormone therapy data, and investigational therapies reshaping treatment in 2025 and beyond.
Evidence-based exercise protocols for managing weight gain during menopause, including resistance training, aerobic programming, and HIIT, with doses and timelines from major clinical trials.
A clinical guide to the conditions that cluster with metabolic syndrome, including type 2 diabetes, cardiovascular disease, NAFLD, PCOS, and sleep apnea, with evidence-based management strategies.
How genetics and family history shape metabolic syndrome risk, which gene variants matter most, and what clinicians recommend for people with inherited predisposition.
NAFLD and MASLD are linked to higher rates of depression, anxiety, fatigue, and cognitive impairment. Learn how metabolic liver disease affects mental health and what treatments address both conditions.
Evidence-based guide to caregiver support, family-based interventions, and practical resources for managing obesity (BMI ≥30), including behavioral strategies, medication awareness, and clinical guidelines from ADA, AACE, and the Endocrine Society.
A clinical review of the most promising obesity trials, next-generation GLP-1 receptor agonists, combination therapies, and gene-based approaches reshaping how we treat BMI ≥30.
How genetics and family history influence obesity risk, BMI heritability, known gene variants like MC4R and FTO, and what this means for GLP-1 and other treatments.
Obesity raises depression risk 55%; depression raises obesity risk 58%. Learn what to monitor and how to treat both conditions together.
Structured exercise programs reduce OSA severity by 25-50% even without weight loss. Review the evidence on aerobic, resistance, and oropharyngeal training protocols for AHI reduction.
Sleep apnea follow-up care: CPAP check at 30 days, clinical review at 3 months, then every 6-12 months with annual cardiometabolic screening.
Evidence-based nutrition, weight-management, and lifestyle interventions for obstructive sleep apnea (OSA), including dietary patterns, GLP-1 receptor agonists, exercise protocols, and positional therapy.
PCOS raises risk for type 2 diabetes, cardiovascular disease, NAFLD, depression, and more. Learn which comorbidities to screen for, when, and how current guidelines direct treatment.
Step-by-step PCOS diagnostic algorithm based on Rotterdam criteria, Endocrine Society guidelines, and AE-PCOS Society recommendations. Covers hyperandrogenism testing, ovulatory assessment, ultrasound criteria, and phenotype classification.
PCOS has a strong genetic component, with heritability estimates of 70%. Learn how family history shapes risk, which genes are involved, and how diagnosis and treatment strategies adapt when PCOS runs in your family.
Evidence-based PCOS monitoring schedule with specific lab tests, imaging timelines, and follow-up intervals recommended by the Endocrine Society, ADA, and AACE guidelines.
A clinical guide to resistance training, high-intensity intervals, and bone-loading exercise during perimenopause, with an evidence-boundary map and a clinician-discussion framework for individualizing the protocol.
Comorbidities like diabetes, obesity, depression, and venous thromboembolism complicate post-surgical recovery. Learn how overlapping conditions affect healing timelines, complications, and treatment planning.
Post-surgical recovery protocol covers three phases: early mobilization (days 0-7), progressive loading (weeks 2-6), and return-to-activity training (weeks 6-12).
A precise, week-by-week monitoring schedule for post-surgical recovery covering labs, wound checks, pain assessment, nutritional support, and when to escalate care.
Complete guide to prediabetes nutrition protocols, lifestyle interventions, and pharmacotherapy options backed by the Diabetes Prevention Program and ADA guidelines.
A step-by-step diagnostic algorithm for secondary hypogonadism, covering morning testosterone testing, LH/FSH interpretation, pituitary imaging, and when to refer, grounded in Endocrine Society and AUA guidelines.
A clinical review of the latest trials, investigational therapies, and guideline updates reshaping how secondary hypogonadism is diagnosed and treated, including oral enclomiphene, kisspeptin agonists, and selective androgen receptor modulators.
How inherited gene variants and familial patterns contribute to secondary hypogonadism, what genetic tests are available, and when clinicians should suspect a hereditary cause.
Evidence-based monitoring schedule for secondary hypogonadism, including lab timing, hormone targets, and follow-up intervals from the Endocrine Society, AUA, and AACE guidelines.
How secondary hypogonadism presents and is managed in obesity, type 2 diabetes, opioid use, HIV, CKD, and other special populations. Evidence-based guidance from the Endocrine Society, ADA, and AACE.
Evidence-based treatment algorithm for secondary hypogonadism, organized by line of therapy. Covers lifestyle modification, clomiphene, enclomiphene, hCG, and testosterone replacement, with attention to what is guideline-supported versus what still needs verification.
A structured, evidence-based algorithm for diagnosing tendinopathy. Covers clinical history, physical examination, imaging, and differential diagnosis across Achilles, patellar, rotator cuff, and lateral elbow tendons.
A guide to exercise-based treatment for tendinopathy, covering eccentric loading, heavy slow resistance, isometric protocols, and progression criteria for Achilles, patellar, rotator cuff, and lateral elbow tendons.
Evidence-based nutrition, supplementation, and lifestyle strategies for tendinopathy recovery. Covers collagen synthesis support, load management, anti-inflammatory dietary patterns, and emerging therapies like BPC-157 and PRP.
Evidence-based guide to caregiver support, family involvement strategies, and community resources for managing Type 2 Diabetes at home.
A clinical guide to the most common comorbidities linked to type 2 diabetes, including cardiovascular disease, CKD, MASLD, obesity, hypertension, depression, and sleep apnea, with evidence-based screening recommendations.
Yes, if two different tests from the same sample both exceed threshold, ADA criteria confirm diabetes. See HbA1c, FPG, and OGTT cutoffs plus screening ages.
Depression and anxiety are 2-3x more common in adults with type 2 diabetes. Learn how the bidirectional relationship affects HbA1c, treatment options, and screening guidelines from the ADA and APA.
See exact test intervals: HbA1c every 3-6 months, annual lipids, UACR and eGFR, dilated eye exam yearly, foot exam every visit, per ADA 2024 standards.
How Type 2 Diabetes management differs across special populations including older adults, pregnant women, adolescents, and those with CKD. Guidelines from ADA, AACE, and Endocrine Society with trial evidence.
Compares GLP-1 RAs, SGLT2 inhibitors, and metformin by cardiorenal benefit, dosing, and tolerability to guide first-line prescribing per ADA 2024.